Presenters: Lorena Lopez-Gonzalez, G1 Therapeutics, Inc; Michelle Moore, RPh, G1 Therapeutics, Inc
Co-Authors: Lowell Hart, MD, Florida Cancer Specialists & Research Institute, Fort Myers, FL; Augustina Ogbonnaya, MPH, Xcenda, Carrolton, TX; Kristen Boykin, PharmD, Florida Cancer Specialists & Research Institute, Fort Myers, FL; Kathryn Deyoung, MS, Xcenda, Carrolton, TX; Ray Bailey, RPh, Florida Cancer Specialists & Research Institute, Fort Myers, FL; Trevor Heritage, PhD, Florida Cancer Specialists & Research Institute, Fort Myers, FL; Lorena Lopez-Gonzalez, PhD, G1 Therapeutics, Inc., Research Triangle Park, NC; Huan Huang, PhD, G1 Therapeutics, Inc., Research Triangle Park, NC; Michelle Moore, RPh, G1 Therapeutics, Inc., Research Triangle Park, NC; Lucio Gordan, MD, Florida Cancer Specialists & Research Institute, Fort Myers, FL
BACKGROUND: Patients with extensive-stage small-cell lung cancer (ES-SCLC) who received chemotherapy frequently have chemotherapy-induced myelosuppression (CIM), leading to the reduced production of white blood cells, red blood cells (RBCs), and/or platelets. Among patients with ES-SCLC who received chemotherapy at Florida Cancer Specialists & Research Institute (FCS) community oncology clinics, the prevalence of grade ≥3 CIM episodes in ≥1 or ≥2 lineages was 62.1% and 33.9%, respectively.1
OBJECTIVE: To evaluate the CIM outcomes of patients with ES-SCLC who received trilaciclib during chemotherapy at FCS clinics.
METHOD: This retrospective cohort study identified adults who received trilaciclib during chemotherapy for ES-SCLC between February 1, 2021, and May 15, 2022, according to FCS-structured electronic medical records. Patients in clinical trials or with <14 days follow-up (except death) were excluded. Descriptive statistics were reported for the prevalence of CIM episodes by type (anemia, thrombocytopenia, neutropenia) and grade across all chemotherapy cycles with trilaciclib. The CIM episodes included events within 21 days from the start of a treatment cycle with trilaciclib administration.
RESULTS: The patients who received trilaciclib (N = 50) were, on average, aged 67.8 years, 56% were female, and 56% were white. During follow-up (median, 2.7 months), 42% of patients had a grade ≥3 CIM episode in ≥1 lineage (anemia: grade 3, 18%; thrombocytopenia: grade 3, 20% and grade 4, 6%; neutropenia: grade 3, 24% and grade 4, 4%). Grade ≥3 CIM episodes in ≥2 lineages occurred in 18% of patients. Supportive care use (eligibility for RBC or platelet transfusion, granulocyte colony-stimulating factor use, erythropoiesis-stimulating agents use, and intravenous hydration) will also be reported.
CONCLUSION: Early real-world outcomes following treatment with trilaciclib suggest a potential for reductions in CIM among patients with ES-SCLC. Future studies are required to confirm the findings.
Previously presented, in part, at 2022 Precision Oncology Summit, October 2022.
- Hart L, Ogbonnaya A, Boykin K, et al. Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: a retrospective study of data from community oncology practices. Poster presented at the Academy of Managed Care Pharmacy Annual Meeting; December 11-14, 2021.